医学
2019年冠状病毒病(COVID-19)
机械通风
重症监护医学
体外膜肺氧合
随机对照试验
食品药品监督管理局
急性呼吸窘迫综合征
标签外使用
疾病
内科学
药理学
肺
传染病(医学专业)
作者
Matthew William McCarthy
标识
DOI:10.1080/14712598.2023.2235269
摘要
INTRODUCTION: ) for the treatment of COVID-19 in hospitalized adults when initiated within 48 hours of receiving invasive mechanical ventilation or extracorporeal membrane oxygenation. AREAS COVERED: Vilobelimab is a human-mouse chimeric IgG4 kappa antibody that targets human complement component 5a, a part of the immune system that is thought to play an important role in the systemic inflammation due to SARS-CoV-2 infection that leads to COVID-19 disease progression. EXPERT OPINION: A pragmatic, adaptive, randomized, multicenter phase II/III study evaluating vilobelimab for the treatment of severe COVID-19 found that patients receiving invasive mechanical ventilation and usual care who were treated with vilobelimab had a lower risk of death by day 28 and day 60 compared to those receiving placebo. This manuscript explores what is known about vilobelimab and explores how this treatment may be used in the future to treat severe COVID-19.
科研通智能强力驱动
Strongly Powered by AbleSci AI